Richmond, Canada
Richmond, Canada

Time filter

Source Type

News Article | May 4, 2017
Site: www.prnewswire.co.uk

Kenya announced its HIV self-testing and PrEP campaigns, BeSelfSure and JipendeJiPrep, earlier today. It features bioLytical's flagship product, INSTI HIV Self Test, as the only blood-based HIV self-test available in its pharmacies. Following the official campaign launch in Kenya, announced today by the National AIDS & STI Control Programme, bioLytical will continue to work with its partners to bring its INSTI HIV Self Test to the people of Kenya, with this KMLTTB certification in place as an indication of its high levels of quality and performance. "We are grateful for the collaborative efforts from numerous stakeholders to help make this happen," says Rick Galli, bioLytical's Chief Technical Officer. "Kenya is leading the way in bringing HIV self-testing into sub-Saharan Africa through the private sector and we are excited to be a part of this ground-breaking initiative that will serve to demonstrate that a low cost, highly accessible HIV self-testing program can be effective and empowering for individuals to take control of their health." "With a network of over 7,000 regulated pharmacies throughout Kenya, this new initiative will allow access to HIV testing that is affordable to most Kenyans across the country through local pharmacies, which are a vital link in the healthcare network," adds Robert Mackie, bioLytical's President. The Kenyan HIV self-testing program will not only involve the distribution of home HIV tests, but will also include a network of support and linkage to care resources for any individuals who test positive. As a first line screening tool, the INSTI HIV Self Test is intended to identify individuals who are likely to be HIV infected and instruct them to go to a clinic as soon as possible for confirmatory testing and counseling on prevention and treatment. For those who test negative, self-testing is an empowering opportunity for individuals to take control of their prevention methods and remain HIV negative. bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform. With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology. bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Hepatitis C and Ebola, among others. The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements. For more information, please visit http://www.biolytical.com.


News Article | April 24, 2017
Site: www.prnewswire.co.uk

As of 2014, of the estimated 2.5 million people in the World Health Organization (WHO) European Region living with HIV, approximately half were not even aware of their status. Locally, estimates suggest nearly 1 in 5 HIV-positive people in Belgium are unaware of their positive status. There are several options available for getting tested, but having access to a very simple yet highly accurate test, allows consumers to test themselves without having to make an appointment at a laboratory, hospital or clinic. "When developing a HIV home test, we wanted to provide an easy, affordable, consumer-friendly solution that would empower individuals to take control of their health in a discrete way, and within the comfort of their own home," said Robert Mackie, bioLytical's President. "By launching in Belgium, we are able to make HIV testing more accessible. INSTI HIV Self Test which can detect HIV up to two weeks sooner than all other HIV home tests currently on the market." The launch in Belgium commenced today with an in-country sales team targeting up to 4,900 pharmacies nationwide. Please email retailsales@biolytical.com for further enquiries to list the INSTI HIV Self Test in your pharmacy. bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform. With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology. bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C and Ebola, among others. The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements. For more information, please visit http://www.biolytical.com.


News Article | April 24, 2017
Site: www.prnewswire.com

bioLytical Laboratories Inc. es una compañía canadiense de propiedad privada implicada en la investigación, desarrollo y comercialización de diagnósticos médicos rápidos e in vitro utilizando su plataforma de tecnología INSTI patentada. Con una huella mundial de aprobaciones regulatorias que incluyen la aprobación de la FDA de Estados Unidos, la aprobación de Health Canada y la Marca CE, bioLytical comercializa y vende su prueba para el VIH de INSTI globalmente y la prueba VIH/sífilis multiplex de INSTI en Europa. La línea de productos INSTI ofrece resultados de pruebas altamente precisos en 60 segundos o menos, mucho más rápido de 15-20 minutos requeridos por las pruebas de competidores basadas en la tecnología de flujo lateral. bioLytical tiene un programa de I+D activo con una línea que incluye pruebas para enfermedades como el Zika, Dengue, Chikungunya, Hepatitis C y Ébola, entre otras. La compañía también ofrece servicios contractuales para adaptar la plataforma INSTI para cubrir los requisitos de pruebas de diagnóstico técnicos y funcionales personalizados. Para más información, visite http://www.biolytical.com.


News Article | May 8, 2017
Site: www.prnewswire.co.uk

The test will be distributed by Pasante Healthcare in the UK through both retail pharmacies and their newly launched INSTI website. Pasante responds to changing views of sexual health and develops products that inspire people to make better, healthier choices - a clear fit for the INSTI HIV Self Test. This partnership further solidifies bioLytical's relationship with Pasante and reinforces Pasante's strength in this field. Livleen Veslemes, bioLytical's Chief Operating Officer, says: 'Pasante has been a long-time partner of INSTI through its distribution of our point of care test. HIV testing has come a long way and Pasante has been on that journey right along with bioLytical so it made sense that the INSTI HIV Self Test be marketed and sold by Pasante in the UK.' With over 1,000,000 INSTI tests already sold to practitioners in the UK, Pasante has grown INSTI to be a market leader in the point of care sector. Consumers can now directly access the same HIV test that is trusted by healthcare professionals and conduct it within the privacy of their own home. Dave Strutt, Pasante's Managing Director, says: 'Having worked with bioLytical for many years within the healthcare field, we know INSTI is leading the way with HIV self-testing, giving people the power to test themselves and find out almost instantly. We want to spread the message far and wide to all those who would like to test at home.' With a single drop of blood, the INSTI HIV Self Test provides instant results and is over 99% accurate.  With other home tests, individuals must wait 15 to 20 minutes (after the test is conducted) for a result to be produced or several days or weeks in the case of laboratory tests. The INSTI HIV Self Test kit includes a resource card that provides information about where to seek help or for those who have general questions on HIV screening. The test is now available online at http://www.hivhometest.com. Issued by Beattie Communications on behalf of bioLytical Laboratories Inc. bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform. With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology. bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C and Ebola, among others. The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements. For more information, please visit http://www.biolytical.com.


News Article | April 24, 2017
Site: www.prnewswire.com

Mit Stand 2014 war rund der Hälfte der geschätzt 2,5 Millionen mit HIV lebenden Menschen in der europäischen Region der Weltgesundheitsorganisation (WHO) ihr Status als HIV-positiv nicht einmal bewusst. Nach Schätzungen vor Ort ist davon auszugehen, dass nahezu ein Fünftel der HIV-positiven Menschen in Belgien nicht wissen, dass sie HIV-positiv sind. Zwar gibt es mehrere Möglichkeiten, sich testen zu lassen, aber der Zugang zu einem sehr einfachen und dennoch hochgenauen Test ermöglicht den Selbsttest, ohne einen Termin in einem Labor, Krankenhaus oder Klinik machen zu müssen. Die Markteinführung in Belgien startete heute mit einem Sales-Team vor Ort, das bis zu 4.900 Apotheken landesweit abdeckt. Für Anfragen und um den INSTI HIV-Selbsttest in ihrer Apotheke zu führen, wenden Sie sich bitte per E-Mail an retailsales@biolytical.com. bioLytical Laboratories Inc. ist ein kanadisches Unternehmen in privater Hand, das sich im Bereich der Erforschung, Entwicklung und Kommerzialisierung schneller medizinischer In Vitro-Diagnosegeräte am Pflegeort unter Verwendung seiner proprietären INSTI-Technologieplattform engagiert. Mit weltweiten Genehmigungen durch Regulierungsbehörden, u. a. durch die US-FDA und Health Canada sowie die CE-Kennzeichnung, vermarktet und verkauft bioLytical seine INSTI-HIV-Tests weltweit und seine INSTI HIV/Syphilis-Multiplex-Tests in Europa. Die INSTI-Produktlinie bietet hochgenaue Testergebnisse in 60 Sekunden oder weniger - wesentlich schneller als die 15 bis 20 Minuten, die bei Tests von Mitbewerbern auf Basis der Lateral-Flow-Technik nötig sind. bioLytical verfügt über ein aktives F&E-Programm mit einer Pipeline, zu der Tests für Krankheiten wie Zika, Denguefieber, Chikungunyafieber, Hepatitis C und Ebola gehören. Das Unternehmen stellt auch Vertragsdienstleistungen zur Verfügung, im Rahmen derer die INSTI-Plattform angepasst wird, um maßgeschneiderte Lösungen für die funktionalen und technischen Diagnosetestanforderungen anzubieten. Weitere Informationen finden Sie unter http://www.biolytical.com.


"Wir sind dankbar für die gemeinsamen Anstrengungen zahlreicher Akteure bei der Realisierung", sagte Rick Galli, technischer Leiter von bioLytical. "Kenia ist federführend bei der Einführung von HIV-Selbsttests durch den privaten Sektor in Afrika südlich der Sahara und wir freuen uns, Teil dieser bahnbrechenden Initiative zu sein. Sie wird zeigen, dass ein kostengünstiges und in hohem Maße verfügbares HIV-Selbsttestprogramm eine Wirkung haben kann und den Einzelnen darin bestärkt, seine Gesundheit in die Hand zu nehmen." bioLytical Laboratories Inc. ist ein kanadisches Privatunternehmen, das im Bereich der Forschung, Entwicklung und Vermarktung von schnellen, medizinischen In-Vitro- und Point-of-Care-Diagnoseverfahren auf Basis seiner urheberrechtlich geschützten INSTI-Technologieplattform tätig ist. Mit weltweiten Genehmigungen unter anderem durch die US-FDA und Health Canada sowie die CE-Zertifizierung vermarktet und verkauft bioLytical seinen INSTI HIV-Test auf der ganzen Welt und den INSTI HIV/Syphilis-Multiplex-Test in Europa. Die INSTI-Produktlinie bietet hochgeradig genaue Testergebnisse innerhalb von maximal 60 Sekunden und damit erheblich schneller als die erforderlichen 15 bis 20 Minuten von Konkurrenzprodukten auf der Grundlage der Lateral-Flo-Technik. bioLytical hat ein aktives F&E-Programm und ist mit der Entwicklung von Tests unter anderem für Krankheiten wie Zika, Hepatitis C und Ebola befasst. Das Unternehmen bietet auch Vertragsdienstleistungen zur Anpassung der INSTI-Plattform an die funktionalen und technischen Anforderungen des Kunden für Diagnosetests. Weitere Informationen finden Sie unter http://www.biolytical.com.


News Article | April 24, 2017
Site: www.prnewswire.com

Avec une simple goutte de sang, l'autotest INSTI VIH offre une précision de plus de 99 % et donne un résultat instantané. Avec d'autres tests à faire chez soi, les personnes doivent attendre entre 15 et 20 minutes (après que le test a été fait) pour obtenir le résultat, ou plusieurs jours ou semaines dans le cas de tests de laboratoires. INSTI est simple à utiliser et offre des résultats efficaces à plus de 99 %. L'autotest INSTI VIH est une adaptation vendue sans ordonnance de l'INSTI pratiqué dans des centres de soins qui a gagné la confiance des professionnels de la santé depuis plus de 10 ans. « Lorsque nous avons développé un test VIH à faire chez soi, nous voulions offrir une solution facile, abordable et conviviale qui donnerait aux personnes la possibilité de prendre leur santé en main en toute discrétion, et dans le confort de leur intérieur », a déclaré Robert Mackie, président de bioLytical. « En lançant le test en Belgique, nous rendons le test du VIH plus accessible. L'autotest INSTI VIH qui peut détecter le virus VIH jusqu'à deux semaines plus tôt tous les autres tests VIH actuellement disponibles sur le marché. » bioLytical Laboratories Inc. est une entreprise canadienne privée, spécialisée dans la recherche, le développement et la commercialisation de tests de diagnostic in vitro rapides en centre de soins reposant sur sa plateforme technologique exclusive INSTI. Avec à son actif une série de certifications à l'échelle mondiale, comprenant notamment des homologations de la FDA (Agence américaine des produits alimentaires et médicamenteux, de Santé Canada et le marquage CE, bioLytical commercialise et vend son test VIH INSTI dans le monde entier et le test INSTI VIH / Syphilis Multiplex en Europe. La gamme INSTI produit des résultats de test extrêmement fiables en 60 secondes ou moins, ce qui s'avère beaucoup plus rapide que les tests concurrents basés sur une technologie de flux latéral, nécessitant généralement 15 à 20 minutes. bioLytical est doté d'un programme de R&D incluant des tests permettant de dépister des maladies telles que le Zika, la dengue, le chikungunya, l'hépatite C et l'Ébola, entre autres. L'entreprise fournit aussi des services contractuels pour adapter la plateforme INSTI aux exigences fonctionnelles et techniques du dépistage personnalisé. Pour de plus amples informations, veuillez visiter http://www.biolytical.com.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to their offering. Did you know? - Lewis Stuart is Vice President, Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing Wantai Biological Pharmacy's Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China. - MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award. - iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development. - Arbor Vita Corporation's flagship product - the OncoE6 Cervical Test - has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care. - On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test. - In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases. These are just a tiny sample of the 1,000's of facts to be found in The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases'. This unique and comprehensive report (360 pages) identifies and profiles the leading 200 developers of in-vitro diagnostics tests for cancer and infectious diseases. They are located right across the globe from the United States and Europe to India and China. The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is perfect for suppliers of raw materials, technology and services to identify top potential customers. This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products. The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is a useful reference tool for in-vitro diagnostic associations. Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 100 of the top companies. For more information about this report visit http://www.researchandmarkets.com/research/zgswvt/the_top_200


Research and Markets has announced the addition of the "The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to their offering. Did you know? - Lewis Stuart is Vice President, Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing Wantai Biological Pharmacy's Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China. - MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award. - iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development. - Arbor Vita Corporation's flagship product - the OncoE6 Cervical Test - has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care. - On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test. - Meridian Bioscience, Inc. reported full-year fiscal 2016 net revenues of $196.1 million. - In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases. These are just a tiny sample of the 1,000's of facts to be found in The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases'. This unique and comprehensive report (360 pages) identifies and profiles the leading 200 developers of in-vitro diagnostics tests for cancer and infectious diseases. They are located right across the globe from the United States and Europe to India and China. 2) Suppliers The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is perfect for suppliers of raw materials, technology and services to identify top potential customers. 3) Distributors This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products. 4) Industry Associations: The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is a useful reference tool for in-vitro diagnostic associations. Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 100 of the top companies. For more information about this report visit http://www.researchandmarkets.com/research/ck84q9/the_top_200


News Article | February 21, 2017
Site: www.prnewswire.com

RICHMOND, BC, Feb. 21, 2017 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease tests, today announced that it has received an Innovative Technology contract from Vizient, Inc., the largest member-owned health care company in the country.  The contract was ba...

Loading bioLytical Laboratories collaborators
Loading bioLytical Laboratories collaborators